Bio Matters: Banker works to build portfolio, vibrant bioscience community

Jim Stafford: Rod Whitson among finalists for Oklahoma Bioscience Association’s 2014 Community Recognition Award.
By Jim Stafford, For The Oklahoman Modified: May 25, 2014 at 10:00 pm •  Published: May 25, 2014
Advertisement
;

When Rod Whitson was recognized by the Oklahoma Bioscience Association in March as one of three finalists for the 2014 Community Recognition Award, the honor caught him by surprise.

Whitson is a banker and an angel investor, which may seem pretty far removed from the bioscience industry.

What he quickly saw, however, was the link between the industry award and his role as an investor whose portfolio is focused in Oklahoma life science companies.

“I think it’s an important award and important acknowledgment because it really does take a community to build an industry cluster,” Whitson said. “So it takes not only just the people directly involved in the industry — the scientists and the entrepreneurs — but it really takes the broader support from the community.

“To be recognized as someone who is doing that is pretty special.”

Whitson is executive vice president of the Banker’s Bank, an Oklahoma City-based, industry owned financial institution that supports community banks throughout Oklahoma and Texas.

A native Oklahoman and American Indian, Whitson began investing in life science companies in the early 2000s while working in San Diego as president of the Townsend Agency, a marketing and public relations firm for the high tech and life sciences industry.

When he returned to Oklahoma in 2008, he brought the means and interest to invest in life science startups with him and signed on as a founding member of the i2E-managed SeedStep Angels group.

Whitson’s Oklahoma portfolio includes Selexys Pharmaceuticals, EpimedX, Moleculera Labs, DermaMedics, Otologic Pharmaceutics and a home health company. He expects to close another investment soon in an Oklahoma City-based diabetes technology company. Whitson typically invests under the name of “6am Capital Partners.”

The No. 1 motivation as a professional investor is to make a nice return on investment, Whitson told me. Early stage bioscience companies, especially medical diagnostic, instrumentation and medical devices meet that criteria.